The reaffirmation of the data readout timeline is a critical piece of information for investors, as it suggests that Affimed's clinical trials are progressing as planned. This can be seen as a positive development, as it keeps the company on track with its expected milestones. The news is likely to be taken well by the market, especially by investors who are focused on the company's pipeline progress. However, the actual impact on the stock price will depend on broader market conditions and investor sentiment towards the biotech sector.